CO2023001559A2 - Anticuerpos fgfr3 y métodos de uso - Google Patents

Anticuerpos fgfr3 y métodos de uso

Info

Publication number
CO2023001559A2
CO2023001559A2 CONC2023/0001559A CO2023001559A CO2023001559A2 CO 2023001559 A2 CO2023001559 A2 CO 2023001559A2 CO 2023001559 A CO2023001559 A CO 2023001559A CO 2023001559 A2 CO2023001559 A2 CO 2023001559A2
Authority
CO
Colombia
Prior art keywords
methods
fgfr3
fgfr3 antibodies
antigen binding
antibodies
Prior art date
Application number
CONC2023/0001559A
Other languages
English (en)
Inventor
Yves Sabbagh
Yangde Chen
William Brondyk
Huawei Qiu
Sunghae Park
Ronnie Wei
Yu Qiu
Yanfeng Zhou
Cendrine Lemoine
Hyunsuk Cho
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2023001559A2 publication Critical patent/CO2023001559A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan proteínas de unión a antígeno anti-FGFR3 y fragmentos de unión a antígeno de las mismas. También se proporcionan métodos para inhibir la actividad de FGFR3 y métodos para tratar trastornos o enfermedades en las que interviene FGFR3.
CONC2023/0001559A 2020-08-21 2023-02-14 Anticuerpos fgfr3 y métodos de uso CO2023001559A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
PCT/US2021/046958 WO2022040560A1 (en) 2020-08-21 2021-08-20 Fgfr3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
CO2023001559A2 true CO2023001559A2 (es) 2023-02-16

Family

ID=77774991

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001559A CO2023001559A2 (es) 2020-08-21 2023-02-14 Anticuerpos fgfr3 y métodos de uso

Country Status (14)

Country Link
US (2) US11505611B2 (es)
EP (1) EP4200019A1 (es)
JP (1) JP2023538098A (es)
KR (1) KR20230052963A (es)
CN (1) CN116323666A (es)
AR (1) AR123306A1 (es)
AU (1) AU2021327387A1 (es)
BR (1) BR112023002455A2 (es)
CA (1) CA3189470A1 (es)
CO (1) CO2023001559A2 (es)
IL (1) IL300623A (es)
MX (1) MX2023002106A (es)
TW (1) TW202229343A (es)
WO (1) WO2022040560A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481000B1 (en) 1989-07-06 1999-05-12 The Regents Of The University Of California Receptors for fibroblast growth factors
ATE141958T1 (de) 1992-06-18 1996-09-15 Whittier Inst Diabetes & Endoc Verfahren zur detektion neoplastischer erkrankungen
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
ES2488240T1 (es) 1999-10-06 2014-08-26 Tigenix N.V. Ensayos in vivo y marcadores moleculares para comprobar la estabilidad fenotípica
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
JP2005530687A (ja) 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
JP2005535629A (ja) 2002-06-27 2005-11-24 ザ ユニバーシティ オブ クイーンズランド 分化調節薬剤およびその使用法
WO2004022095A1 (en) 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
EP1611252B1 (en) 2003-03-26 2009-07-29 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1544213B1 (en) 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
ATE533853T1 (de) 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
EP1824513A4 (en) 2004-11-04 2010-06-09 Fibron Ltd TREATMENT OF B-CELL TUMORS
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
EP1752471B9 (en) 2005-01-05 2009-04-15 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940873A2 (en) 2005-10-17 2008-07-09 Enkam Pharmaceuticals A/S Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
US8158360B2 (en) 2005-12-08 2012-04-17 Novartis Ag Effects of inhibitors of FGFR3 on gene transcription
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CA2683804A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
MX2010012616A (es) 2008-05-29 2010-12-21 Galaxy Biotech Llc Anticuerpos monoclonales para factor de crecimiento de fibroblastos basico.
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
CN104788564A (zh) 2009-03-25 2015-07-22 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
US20120328599A1 (en) 2010-01-14 2012-12-27 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
JP6107812B2 (ja) 2012-03-08 2017-04-05 アステラス製薬株式会社 新規ｆｇｆｒ３融合体
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN111269880A (zh) 2013-04-05 2020-06-12 大学健康网络 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
CA2976638A1 (en) 2015-02-19 2016-08-25 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
JP2020506945A (ja) 2017-02-06 2020-03-05 レーニア セラピューティクス インコーポレイテッド がんの治療のための方法、組成物及びキット

Also Published As

Publication number Publication date
MX2023002106A (es) 2023-03-15
BR112023002455A2 (pt) 2023-03-28
CN116323666A (zh) 2023-06-23
KR20230052963A (ko) 2023-04-20
TW202229343A (zh) 2022-08-01
US11505611B2 (en) 2022-11-22
CA3189470A1 (en) 2022-02-24
US20220056142A1 (en) 2022-02-24
AU2021327387A9 (en) 2023-07-06
EP4200019A1 (en) 2023-06-28
AU2021327387A1 (en) 2023-05-04
WO2022040560A1 (en) 2022-02-24
JP2023538098A (ja) 2023-09-06
AR123306A1 (es) 2022-11-16
US20230303704A1 (en) 2023-09-28
IL300623A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022014623A2 (pt) Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
MD3601358T2 (ro) Anticorpi anti-TREM2 și metode de utilizare a acestora
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BRPI0514124A (pt) anticorpos monoclonais humanos contra a il-4 humana
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
CO2023001559A2 (es) Anticuerpos fgfr3 y métodos de uso
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112021018632A2 (pt) Moléculas de ligação ao cd3
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados